As per Future Market Insights, the global unresectable hepatocellular carcinoma market is anticipated to attain a value pool of USD 2,200 million by 2023-end. Global demand for unresectable hepatocellular carcinoma treatment is expected to rise at a CAGR of 7.2% to USD 4,400 million in 2033.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value in 2023 | USD 2,200 million |
| Projected Market Value in 2033 | USD 4,400 million |
| Growth Rate (2023 to 2033) | 7.2% CAGR |
This Unresectable Hepatocellular Carcinoma market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape.
Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Unresectable Hepatocellular Carcinoma market.
Cancer is most common disease which has higher mortality rate. Hepatocellular Carcinoma (HCC) is an aggressive tumor disorder which occurs in patients associated with chronic liver disease and cirrhosis. In unresectable hepatocellular carcinoma, surgical and liver-directed non-surgical treatment is not appropriate.
However, systemic therapy using various methods can be used in patients suffering from unresectable hepatocellular carcinoma. Based on a study in the USA for every 100,000 people, there are six new cases of HCC and incidence has increased over last four decades.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Several new treatments are being developed to treat unresectable HCC, including immunotherapy, targeted therapy, and local ablative therapies. Immunotherapy has shown promise in the treatment of HCC, with drugs such as nivolumab and pembrolizumab demonstrating improved overall survival in clinical trials.
Targeted therapy is also an active area of research, with drugs such as sorafenib and lenvatinib being approved for the treatment of unresectable HCC. These drugs target specific molecular pathways involved in the growth and progression of HCC, offering a new approach to treatment.
The increasing demand for advanced treatments and the approval of new drugs is expected to drive continued growth in the market for the unresectable HCC in the coming years.
This growth is likely to be accompanied by an increase in healthcare expenditure, as patients and healthcare providers seek out new and more effective treatments for this condition.
The North American market for unresectable Hepatocellular Carcinoma (HCC) is a rapidly developing and dynamic market. The increasing incidence of HCC in the region, driven by factors such as aging populations, obesity, and increasing rates of viral hepatitis, has resulted in a growing demand for effective treatments for this condition.
In response to this demand, a number of new treatments for unresectable HCC are being developed in North America. These include immunotherapy, targeted therapy, and local ablative therapies. The approval of drugs such as nivolumab and pembrolizumab for the treatment of unresectable HCC has demonstrated the potential of immunotherapy in this field.
Targeted therapy is also an active area of research, with drugs such as sorafenib and lenvatinib being approved for the treatment of unresectable HCC in North America.
The growing demand for advanced treatments and the increasing incidence of HCC is expected to result in increased healthcare expenditure in North America. Patients and healthcare providers are seeking out new and more effective treatments for unresectable HCC, which is expected to drive continued growth in the market in the coming years.
Principal Consultant
The most lucrative end user segment in the market for unresectable Hepatocellular Carcinoma (HCC) is the hospital and specialty clinic segment. Hospitals and speciality clinics are the primary providers of healthcare services for patients with HCC, and they represent a prominent source of revenue for companies in this market.
Hospitals and specialty clinics offer a wide range of diagnostic and therapeutic services for patients with HCC, including imaging tests, biopsy procedures, and treatments such as chemotherapy and radiation therapy.
As a result, they are a critical component of the healthcare ecosystem for patients with HCC and play a crucial role in the treatment of this condition.
As patients seek out new and more effective treatments for unresectable HCC, hospitals and specialty clinics are expanding their offerings of diagnostic and therapeutic services, which are expected to result in increased revenue for companies in this market.
High incidence rate of liver carcinoma is expected to drive the unresectable hepatocellular carcinoma market. Unmet market demand for new treatment options is expected to drive the unresectable hepatocellular carcinoma market. Increasing research funding by industry players is expected to fuel the growth of table hepatocellular carcinoma market.
However, the diagnosis in general population is very less and poor efficacy of current therapeutic agents may hinder the growth of unresectable hepatocellular carcinoma market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Unresectable hepatocellular carcinoma market has high potential due to unmet demand for patient care and huge opportunity for alternative novel treatment options. Based on the systemic treatment segmentation, chemotherapy is expected to lead unresectable hepatocellular carcinoma market in the future.
Recently in 2018, FDA approved Lenvatinib capsules (Lenvima) manufactured by Eisai Inc., which is used as a first-line of treatment for unresectable hepatocellular carcinoma. Emerging therapies are majorly focused on Ramucirumab, Cabozantinib for the treatment of unresectable hepatocellular carcinoma.
The global unresectable hepatocellular carcinoma market is expected to be dominated by North America due to high treatment adoption rate. Europe is expected to be the second most lucrative region in the global unresectable hepatocellular carcinoma market owing to higher healthcare expenditure.
Latin America is emerging region for unresectable hepatocellular carcinoma market and is estimated to show high growth owing to increasing early diagnosis of disease.
East Asia and South Asia unresectable hepatocellular carcinoma market are expected to show significant growth due to improving healthcare infrastructure. Middle East and Africa is expected to be the least lucrative due to low awareness and poor economic conditions.
Examples of some of the market participants in unresectable hepatocellular carcinoma market identified across the value chain include Eisai Co., Ltd, Bayer AG, Bristol- Myers Squibb Company, Sumitomo Dainippon Pharma Co., Ltd, Glaxosmithkline Plc, Exelixis, Inc, Eli Lilly and Company, Merck & Co., Inc., Incyte Corp, Novartis AG, F. Hoffmann-La Roche Ltd, Astrazeneca Plc, Pfizer Inc, Celgene Corporation, Sanofi S.A., and Others.
The research report on unresectable hepatocellular carcinoma market presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies.
The research report on unresectable hepatocellular carcinoma market provides analysis and information according to market segments such as geographies, application, and end user.
The report on unresectable hepatocellular carcinoma market is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
The global unresectable hepatocellular carcinoma market is classified on the basis of systemic treatment, end user, and region
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Systemic Treatment 6.2. End User 7. Global Market Analysis and Forecast, By Systemic Treatment 7.1. Chemotherapy 7.2. Molecularly Targeted Therapy 7.3. Immunotherapy 8. Global Market Analysis and Forecast, By End User 8.1. Hospitals 8.2. Specialty Clinics 8.3. Cancer Centers 8.4. Research Institutes 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. East Asia 9.5. South Asia 9.6. Oceania 9.7. The Middle East and Africa (MEA) 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Europe Sales Analysis and Forecast, by Key Segments and Countries 13. East Asia Sales Analysis and Forecast, by Key Segments and Countries 14. South Asia Sales Analysis and Forecast, by Key Segments and Countries 15. Oceania Sales Analysis and Forecast, by Key Segments and Countries 16. The Middle East and Africa (MEA) Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Systemic Treatment and End User for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Eisai Co., Ltd 19.2. Bayer AG 19.3. Bristol-Myers Squibb Company 19.4. Sumitomo Dainippon Pharma Co., Ltd 19.5. GlaxoSmithKline Plc 19.6. Exelixis, Inc 19.7. Eli Lilly and Company 19.8. Merck & Co., Inc. 19.9. Incyte Corp 19.10. Novartis AG, F. Hoffmann-La Roche Ltd 19.11. AstraZeneca Plc 19.12. Pfizer Inc 19.13. Celgene Corporation 19.14. Sanofi S.A.
Explore Healthcare Insights
View Reports
Unresectable Hepatocellular Carcinoma Market
